JAMP ALLOPURINOL 200 MG
ALLOPURINOL : 200 MG · DIN 02421607 · JAMP PHARMA CORPORATION
Health Canada status: MARKETED
What is JAMP ALLOPURINOL?
JAMP ALLOPURINOL 200 MG contains ALLOPURINOL : 200 MG. It is listed in the Health Canada Drug Product Database under DIN 02421607, held by JAMP PHARMA CORPORATION, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 20-Mar-2025. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is JAMP ALLOPURINOL used for?
JAMP Allopurinol (allopurinol) is indicated for: Treatment of gout, either primary, or secondary to hyperuricemia which occurs in blood dyscrasias and their therapy. Treatment of primary or secondary uric acid nephropathy, with or without accompanying signs or symptoms of gout. Prophylactically, to prevent tissue urate deposition or renal calculi in patients with leukemias, lymphomas or other malignancies, receiving antineoplastic treatment (radiation or cytotoxic drugs) which might induce increased uricemia levels. Also in the therapy and prophylaxis of acute urate nephropathy and resultant renal failure in patients with neoplastic disease who are particularly susceptible to hyperuricemia and uric acid stone formation (especially after radiation therapy or use of antineoplastic drugs). Prevention of the occurrence and recurrence of uric acid stones or gravel and renal calcium lithiasis in patients with hyperuricemia and/or hyperuricosuria.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02421607 |
|---|---|
| Brand name | JAMP ALLOPURINOL |
| Generic / active ingredient | ALLOPURINOL : 200 MG |
| Manufacturer | JAMP PHARMA CORPORATION |
| Strength | 200 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | M04AA01 ALLOPURINOL |
| AHFS class | 92:16.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 20-Mar-2025 |
| Original market date | 2014-03-10 00:00:00 |
How is it stored and handled?
null
How is it supplied?
JAMP Allopurinol 100 mg: Available in bottles of 100 and 1000 tablets. JAMP Allopurinol 200 mg: Available in bottles of 100 and 500 tablets. JAMP Allopurinol 300 mg: Available in bottles of 100 tablets.
What can be used instead?
Other Canadian products sharing ATC code M04AA01 ALLOPURINOL. 12 of 51 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ALLOPURINOL-100 | 100 MG | TABLET | PRO DOC LIMITEE | MARKETED | DIN 00555681 |
| ALLOPURINOL-200 | 200 MG | TABLET | PRO DOC LIMITEE | MARKETED | DIN 02130157 |
| ALLOPURINOL-300 | 300 MG | TABLET | PRO DOC LIMITEE | MARKETED | DIN 00555703 |
| APO-ALLOPURINOL TABLETS | 100 MG | TABLET | APOTEX INC | MARKETED | DIN 00402818 |
| APO-ALLOPURINOL TABLETS | 200 MG | TABLET | APOTEX INC | MARKETED | DIN 00479799 |
| APO-ALLOPURINOL TABLETS | 300 MG | TABLET | APOTEX INC | MARKETED | DIN 00402796 |
| JAMP ALLOPURINOL | 100 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02421593 |
| JAMP ALLOPURINOL | 300 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02421615 |
| MAR-ALLOPURINOL | 100 MG | TABLET | MARCAN PHARMACEUTICALS INC | MARKETED | DIN 02396327 |
| MAR-ALLOPURINOL | 200 MG | TABLET | MARCAN PHARMACEUTICALS INC | MARKETED | DIN 02396335 |
Who else supplies ALLOPURINOL worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. ALLOPURINOL appears in 369 registered pack listings across 14 markets, published on 11 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.